company_id	company_name	company_type	drug_id	name	phase_highest	indications	technologies	therapy_areas	termination_phase
1118745	AbCellera Biologics	ancestor	160563	undisclosed G-protein coupled receptor targeted antibody (VelocImmune, undisclosed indication), AbCellera Biologics/Regeneron Pharmaceuticals	Discovery	['Unidentified indication']	['Biological therapeutic', 'Monoclonal antibody']	['Unknown']	
1118745	AbCellera Biologics	ancestor	129607	TTG-108	Discovery	['Pain', 'Peripheral neuropathy']	['Biological therapeutic', 'Monoclonal antibody']	['Neurology/Psychiatric']	
1118745	AbCellera Biologics	ancestor	111217	OmniAb program, TetraGenetics	Preclinical	['Unidentified indication']	['Biological therapeutic', 'Humanized antibody']	['Unknown']	
1118745	AbCellera Biologics	ancestor	108497	Kv1.3 ion channel mAbs (autoimmune disorder), Tetragenetics	Preclinical	['Autoimmune disease', 'Insulin dependent diabetes']	['Biological therapeutic', 'Monoclonal antibody humanized', 'Recombinant monoclonal antibody therapy']	['Endocrine/Metabolic', 'Immune']	
1118745	AbCellera Biologics	ancestor	105034	KCa3.1 ion channel targeting antibodies (autoimmune disorder), Tetragenetics	Discovery	['Autoimmune disease']	['Antibody therapy', 'Biological therapeutic', 'Parenteral formulation unspecified']	['Immune']	
1118745	AbCellera Biologics	ancestor	132905	bebtelovimab	Phase 2 Clinical	['Coronavirus disease 19 infection']	['Biological therapeutic', 'Immunoglobulin G isotype antibody', 'Intravenous formulation', 'Monoclonal antibody human']	['Infection']	
1118745	AbCellera Biologics	ancestor	122922	bamlanivimab	Launched	['Coronavirus disease 19 infection']	['Biological therapeutic', 'Human monoclonal antibody therapy', 'Infusion', 'Intravenous formulation', 'Monoclonal antibody human', 'Virus recombinant']	['Infection']	
1118745	AbCellera Biologics	ancestor	110952	monoclonal antibodies (neurodegenerative disease), AbCellera/ Denali	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody']	['Neurology/Psychiatric']	Discovery
1118745	AbCellera Biologics	ancestor	102881	fully human antibodies (Ebola virus infection), AbCellera/MassBiologics	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody human', 'Parenteral formulation unspecified']	['Infection']	Discovery
1118745	AbCellera Biologics	ancestor	102880	fully human antibodies (E coli infection), AbCellera/MassBiologics	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody human', 'Parenteral formulation unspecified']	['Infection']	Discovery
1051398	Tetragenetics Inc	subsidiary	84249	antimalarial vaccine, Tetragenetics	No Development Reported	[]	['Biological therapeutic']	['Infection']	Discovery
1051398	Tetragenetics Inc	subsidiary	75394	recombinant H5N1 vaccine (G-SOME nanoparticle), Tetragenetics	No Development Reported	[]	['Biological therapeutic', 'Nanoparticle formulation', 'Parenteral formulation unspecified', 'Protein recombinant']	['Infection']	Discovery
1051398	Tetragenetics Inc	subsidiary	102216	Nav1.6 / Kv10.1 ion channel targeting mAbs (pain/ autoimmune disorder), Tetragenetics	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody']	['Neurology/Psychiatric', 'Immune']	Discovery
1156628	Accutar Biotech	ancestor	151059	AC-699	Phase 1 Clinical	['Metastatic breast cancer']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1156628	Accutar Biotech	ancestor	140970	AC-0676	Phase 1 Clinical	['Acute lymphoblastic leukemia', 'Autoimmune disease', 'B-cell lymphoma', 'Chronic lymphocytic leukemia', 'Diffuse large B-cell lymphoma', 'Follicle center lymphoma', 'Hematological neoplasm', 'Lymphoplasmacytic lymphoma', 'Mantle cell lymphoma', 'Small lymphocytic lymphoma', 'Splenic marginal zone lymphoma']	['Oral formulation', 'Proteolysis targeting chimera agent', 'Small molecule therapeutic']	['Cancer', 'Immune']	
1156628	Accutar Biotech	ancestor	139290	AC-0176	Phase 1 Clinical	['Hormone refractory prostate cancer']	['Biological therapeutic', 'Capsule formulation', 'Oral formulation', 'Protein chimeric', 'Receptor chimeric']	['Cancer']	
1156628	Accutar Biotech	ancestor	138190	small molecule therapeutic (lung cancer), Accutar Biotechnology	Discovery	['Lung tumor']	['Small molecule therapeutic']	['Cancer']	
1156628	Accutar Biotech	ancestor	138189	undisclosed drug (solid tumor), Accutar Biotechnology	Discovery	['Solid tumor']	['Small molecule therapeutic']	['Cancer']	
1156628	Accutar Biotech	ancestor	129505	AC-682	Phase 1 Clinical	['Metastatic breast cancer']	['Biological therapeutic', 'Oral formulation', 'Protein chimeric', 'Receptor chimeric']	['Cancer']	
1080710	Adagene	ancestor	144771	ADG-138	Preclinical	['Solid tumor']	['Biological therapeutic', 'Bispecific T cell engager antibody', 'Immuno-oncology', 'Systemic formulation unspecified']	['Cancer']	
1080710	Adagene	ancestor	142128	ADG-206	Phase 1 Clinical	['Advanced solid tumor', 'Cancer']	['Antibody therapy', 'Biological therapeutic', 'Immuno-oncology', 'Infusion', 'Intravenous formulation', 'Prodrug']	['Cancer']	
1080710	Adagene	ancestor	142076	CD28 TCE	Preclinical	['Cancer']	['Biological therapeutic', 'Bispecific T cell engager antibody', 'Immuno-oncology', 'Prodrug']	['Cancer']	
1080710	Adagene	ancestor	139172	ADG-153	Preclinical	['Cancer', 'Hematological neoplasm', 'Solid tumor']	['Biological therapeutic', 'Immuno-oncology', 'Immunoglobulin G isotype antibody', 'Monoclonal antibody human', 'Prodrug']	['Cancer']	
1080710	Adagene	ancestor	138826	ADG-152	Preclinical	['Cancer']	['Biological therapeutic', 'Bispecific T cell engager antibody', 'Immuno-oncology', 'Infusion', 'Intravenous formulation', 'Prodrug']	['Cancer']	
1080710	Adagene	ancestor	129944	BC-006, Dragonboat Biopharmaceutical	Phase 1 Clinical	['Advanced solid tumor', 'Asthma', 'Autoimmune disease', 'Benign tumor']	['Biological therapeutic', 'Immunoglobulin G isotype antibody', 'Injectable formulation', 'Monoclonal antibody humanized', 'Systemic formulation unspecified']	['Immune', 'Respiratory', 'Cancer']	
1080710	Adagene	ancestor	129069	ADG-126	Phase 2 Clinical	['Advanced solid tumor']	['Biological therapeutic', 'Immuno-oncology', 'Immunoglobulin G isotype antibody', 'Infusion', 'Intravenous formulation', 'Monoclonal antibody human']	['Cancer']	
1080710	Adagene	ancestor	119189	ADG-116	Phase 2 Clinical	['Advanced solid tumor', 'Non-Hodgkin lymphoma']	['Biological therapeutic', 'Immuno-oncology', 'Infusion', 'Intravenous formulation', 'Monoclonal antibody human']	['Cancer']	
1080710	Adagene	ancestor	116059	masked ADC (undisclosed target, SAFEbody, PBD-based payload, solid tumor), Adagene/ ADC Therapeutics	Discovery	['Solid tumor']	['Antibody drug conjugate', 'Biological therapeutic']	['Cancer']	
1080710	Adagene	ancestor	112326	ADG-104	Phase 2 Clinical	['Cancer', 'Metastatic bladder cancer', 'Metastatic renal cancer', 'Penis tumor']	['Biological therapeutic', 'Immuno-oncology', 'Immunoglobulin G isotype antibody', 'Intravenous formulation', 'Monoclonal antibody human']	['Cancer']	
1080710	Adagene	ancestor	111497	ADG-106	Phase 2 Clinical	['Advanced solid tumor', 'Breast tumor', 'Metastatic non small cell lung cancer', 'Non-Hodgkin lymphoma']	['Biological therapeutic', 'Immuno-oncology', 'Immunoglobulin G isotype antibody', 'Infusion', 'Intravenous formulation', 'Monoclonal antibody human']	['Cancer']	
1084743	AI Therapeutics	ancestor	99989	apilimod dimesylate (capsule, B-cell non-Hodgkins lymphoma/Chronic lymphocytic leukemia/amyotrophic lateral sclerosis), AI Therapeutics	Phase 2 Clinical	['Chronic lymphocytic leukemia', 'Coronavirus disease 19 infection', 'Diffuse large B-cell lymphoma', 'Follicle center lymphoma', 'Mantle cell lymphoma', 'Marginal zone B-cell lymphoma', 'Motor neurone disease', 'Non-Hodgkin lymphoma', 'Primary mediastinal large B-cell lymphoma', 'Small lymphocytic lymphoma']	['Capsule formulation', 'Immuno-oncology', 'Oral formulation', 'Small molecule therapeutic']	['Infection', 'Cancer', 'Neurology/Psychiatric']	
1084743	AI Therapeutics	ancestor	67349	AIT-102	Preclinical	['Colorectal tumor', 'Ewing sarcoma', 'Lung tumor', 'Soft tissue sarcoma', 'Solid tumor']	['Intravenous formulation', 'Natural product', 'Small molecule therapeutic']	['Cancer']	
1084743	AI Therapeutics	ancestor	121780	rapamycin (topical, tuberous sclerosis complex -facial angiofibroma, skin disease), AI Therapeutics	Phase 2 Clinical	['Dermatological disease', 'Tuberous sclerosis']	['Dermatological formulation', 'Small molecule therapeutic']	['Dermatologic', 'Neurology/Psychiatric']	
1084743	AI Therapeutics	ancestor	100835	sirolimus (inhaled, lymphangioleiomyomatosis/pulmonary artery hypertension/tuberous sclerosis complex), AI Therapeutics	Phase 2 Clinical	['Bronchiolitis', 'Bronchiolitis obliterans syndrome', 'Lymphangioleiomyomatosis', 'Pulmonary artery hypertension', 'Sarcoidosis', 'Tuberous sclerosis']	['Inhalant formulation', 'Small molecule therapeutic']	['Cancer', 'Cardiovascular', 'Respiratory', 'Inflammatory', 'Neurology/Psychiatric']	
1084743	AI Therapeutics	ancestor	121781	LAM–005	No Development Reported	[]	['Small molecule therapeutic']	['Unknown']	Preclinical
1084743	AI Therapeutics	ancestor	105730	LAM-003	No Development Reported	[]	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	Phase 1 Clinical
1196876	ArsenalBio	ancestor	164387	integrated circuit CAR T-cells (AND logic-gated CAR + SPA.I, solid tumors), Arsenal Biosciences	Preclinical	['Solid tumor']	['Biological therapeutic', 'Chimeric antigen receptor T cell therapy', 'Immuno-oncology', 'Infusion', 'Intravenous formulation', 'Protein fusion', 'Receptor chimeric', 'T-lymphocyte']	['Cancer']	
1196876	ArsenalBio	ancestor	164263	AB-2100	Preclinical	['Renal cell carcinoma']	['Biological therapeutic', 'Chimeric antigen receptor T cell therapy', 'Immuno-oncology', 'Infusion', 'Intravenous formulation', 'Protein fusion', 'Receptor chimeric', 'T-lymphocyte']	['Cancer']	
1196876	ArsenalBio	ancestor	138548	AB-1015	Phase 1 Clinical	['Fallopian tube tumor', 'Metastatic ovary cancer', 'Ovary tumor', 'Peritoneal tumor']	['Biological therapeutic', 'Chimeric antigen receptor T cell therapy', 'Immuno-oncology', 'Infusion', 'Intravenous formulation', 'Protein fusion', 'Receptor chimeric', 'T-lymphocyte']	['Cancer']	
1139692	Atomwise	ancestor	143127	undisclosed drug program (Rett Syndrome), Vyant Bio Inc/Atomwise Inc	Preclinical	['Rett syndrome']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1138966	BenevolentAI	ancestor	148583	drug candidate (cancer), BenevolentAI	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1138966	BenevolentAI	ancestor	148579	drug candidate (idiopathic pulmonary fibrosis), BenevolentAI/AstraZeneca	Discovery	['Idiopathic pulmonary fibrosis']	['Small molecule therapeutic']	['Respiratory']	
1138966	BenevolentAI	ancestor	148577	drug candidate (Parkinson’s disease), BenevolentAI	Discovery	['Parkinsons disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1138966	BenevolentAI	ancestor	143747	undisclosed program (CNS disease), BenevolentAI	Discovery	['Central nervous system disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1138966	BenevolentAI	ancestor	142495	HTL-30023	Preclinical	['Intestine disease', 'Non-alcoholic steatohepatitis']	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Gastrointestinal']	
1138966	BenevolentAI	ancestor	141352	undisclosed drug target (antiviral), BenevolentAI	Discovery	['Unidentified indication']	['Small molecule therapeutic']	['Unknown']	
1138966	BenevolentAI	ancestor	140688	undisclosed target program (chronic kidney disease) , AstraZeneca/BenevolentAI	Discovery	['End stage renal disease']	['Small molecule therapeutic']	['Genitourinary/Sexual Function']	
1138966	BenevolentAI	ancestor	140273	undisclosed program (non alcoholic steatohepatitis), BenevolentAI	Discovery	['Non-alcoholic steatohepatitis']	['Small molecule therapeutic']	['Gastrointestinal']	
1138966	BenevolentAI	ancestor	140269	BEN-28010	Preclinical	['Glioblastoma']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1138966	BenevolentAI	ancestor	140261	undisclosed program (inflammatory bowel disease), BenevolentAI	Discovery	['Inflammatory bowel disease']	['Small molecule therapeutic']	['Gastrointestinal']	
1138966	BenevolentAI	ancestor	138085	BEN-8744	Phase 1 Clinical	['Ulcerative colitis']	['Oral formulation', 'Small molecule therapeutic']	['Gastrointestinal']	
1138966	BenevolentAI	ancestor	137787	repurposed vandetanib + everolimus (diffuse intrinsic pontine glioma), BenevolentAI/Institute of Cancer Research UK	Clinical	['Glioma']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1138966	BenevolentAI	ancestor	125571	BEN-1391	Preclinical	['Insomnia']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1138966	BenevolentAI	ancestor	116591	BEN-9160	Preclinical	['Motor neurone disease']	['Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	
1138966	BenevolentAI	ancestor	125572	BEN-2293	Discontinued	[]	['Dermatological formulation', 'Small molecule therapeutic']	['Dermatologic']	Phase 2 Clinical
1141944	BenevolentBio	subsidiary	59161	bavisant	Phase 2 Clinical	['Hypersomnia']	['Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric', 'Toxicity/Intoxication']	
1141944	BenevolentBio	subsidiary	112212	BEN-1589	Discovery	['Allergic rhinitis']	['Small molecule therapeutic']	['Immune']	
1141944	BenevolentBio	subsidiary	106416	BEN-34712	Preclinical	['Motor neurone disease']	['Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	
1141944	BenevolentBio	subsidiary	104068	Alzheimer's disease therapy, BenevolentBio	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1184789	BIOAGE LABS	ancestor	59000	asapiprant	Phase 2 Clinical	['Aging', 'Coronavirus disease 19 infection', 'Infectious disease', 'Influenza virus infection', 'Respiratory syncytial virus infection']	['Oral formulation', 'Small molecule therapeutic', 'Tablet formulation']	['Other/Miscellaneous', 'Immune', 'Infection']	
1184789	BIOAGE LABS	ancestor	162284	Unspecified drug target (brain aging), BioAge Labs	Discovery	['Aging']	['Small molecule therapeutic']	['Other/Miscellaneous']	
1184789	BIOAGE LABS	ancestor	162283	APJ agonist (brain aging), BioAge Labs	Discovery	['Aging']	['Small molecule therapeutic']	['Other/Miscellaneous']	
1184789	BIOAGE LABS	ancestor	159303	NLRP3 inhibitor (ocular topical, Dry eye disease), BioAge Labs	Discovery	['Aging', 'Ocular inflammation', 'Xerophthalmia']	['Ophthalmic formulation', 'Ophthalmic liquid formulation', 'Small molecule therapeutic']	['Ocular', 'Other/Miscellaneous']	
1184789	BIOAGE LABS	ancestor	159204	azelaprag (oral, prevention of muscle aging), BioAge Labs	Phase 1 Clinical	['Aging', 'Atrophy']	['Oral formulation', 'Small molecule therapeutic']	['Musculoskeletal', 'Other/Miscellaneous']	
1184789	BIOAGE LABS	ancestor	145361	NLRP3 inhibitor progam (oral, inflammatory diseases/age-related disease/parkinson's disease), BioAge Labs	Preclinical	['Aging', 'Inflammatory disease', 'Parkinsons disease']	['CNS formulation', 'Oral formulation', 'Small molecule therapeutic']	['Other/Miscellaneous', 'Neurology/Psychiatric', 'Inflammatory']	
1184789	BIOAGE LABS	ancestor	104209	BGE-117	Phase 2 Clinical	['Aging', 'Anemia']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Other/Miscellaneous', 'Hematologic']	
1184789	BIOAGE LABS	ancestor	103960	azelaprag (iv, prevention of muscle aging), BioAge Labs	Phase 1 Clinical	['Aging', 'Atrophy', 'Myopathy']	['Infusion', 'Intravenous formulation', 'Small molecule therapeutic']	['Cardiovascular', 'Other/Miscellaneous', 'Neurology/Psychiatric', 'Musculoskeletal']	
1102582	BioXcel Therapeutics	ancestor	171027	BXCL-504	Discovery	['Neurological disease']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1102582	BioXcel Therapeutics	ancestor	171025	BXCL-503	Discovery	['Neurological disease']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1102582	BioXcel Therapeutics	ancestor	100906	BXCL-502	Preclinical	['Agitation', 'Alzheimers disease', 'Central nervous system disease', 'Dementia', 'Psychiatric disorder']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1102582	BioXcel Therapeutics	ancestor	100905	dexmedetomidine (sublingual, agitation), BioXcel Therapeutics	Launched	['Agitation', 'Alcohol withdrawal syndrome', 'Alzheimers disease', 'Bipolar I disorder', 'Bipolar II disorder', 'Delirium', 'Dementia', 'Drug withdrawal syndrome', 'Major depressive disorder', 'Opiate dependence', 'Post traumatic stress disorder', 'Schizoaffective disorder', 'Schizophrenia', 'Schizophreniform disorder']	['Buccal formulation systemic', 'Film coating', 'Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric', 'Toxicity/Intoxication']	
1102582	BioXcel Therapeutics	ancestor	106446	BXCL-904	No Development Reported	[]	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Endocrine/Metabolic']	Preclinical
1102582	BioXcel Therapeutics	ancestor	106443	BXCL-903	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1102582	BioXcel Therapeutics	ancestor	106442	BXCL-902	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Preclinical
1102582	BioXcel Therapeutics	ancestor	106440	BXCL-901	No Development Reported	[]	['Small molecule therapeutic']	['Hematologic']	Preclinical
1102582	BioXcel Therapeutics	ancestor	106439	sodium stibogluconate (hematological malignancies), BioXcel	No Development Reported	[]	['Intravenous formulation', 'Small molecule therapeutic']	['Cancer']	Phase 1 Clinical
1102582	BioXcel Therapeutics	ancestor	106046	talabostat (cancer), BioXcel	Phase 2 Clinical	['Hormone refractory prostate cancer', 'Metastatic pancreas cancer', 'Pancreas tumor', 'Pancreatic ductal adenocarcinoma', 'Prostate tumor', 'Small-cell lung cancer']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1102582	BioXcel Therapeutics	ancestor	100907	bortezomib (neurofibromatosis type 2), BioXcel	No Development Reported	[]	['Small molecule therapeutic', 'Subcutaneous formulation']	['Cancer']	Phase 1 Clinical
1213568	Cellarity	ancestor	139546	CLT-1081	Preclinical	['Sickle cell anemia']	['Small molecule therapeutic']	['Hematologic']	
1164801	Celsius Therapeutics	ancestor	146261	undisclosed T/NK cells checkpoint inhibitor (solid tumor), Celsius Therapeutics	Discovery	['Solid tumor']	['Biological therapeutic', 'Immuno-oncology']	['Cancer']	
1164801	Celsius Therapeutics	ancestor	145448	Ledenika mAb program (solid tumor), Celsius Therapeutics	Discovery	['Solid tumor']	['Biological therapeutic', 'Monoclonal antibody']	['Cancer']	
1164801	Celsius Therapeutics	ancestor	145411	Myeloid activating target (inflammatory bowel disease/ulcerative colitis /crohn's disease), Celsius Therapeutics	Discovery	['Crohns disease', 'Inflammatory bowel disease', 'Ulcerative colitis']	['Small molecule therapeutic']	['Gastrointestinal']	
1164801	Celsius Therapeutics	ancestor	144501	Lassen mAb (solid tumor), Celsius Therapeutics	Discovery	['Breast tumor']	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	
1164801	Celsius Therapeutics	ancestor	143709	undisclosed therapeutic (colorectal cancer), Celsius Therapeutics/Servier	Discovery	['Colorectal tumor']	['Small molecule therapeutic']	['Cancer']	
1164801	Celsius Therapeutics	ancestor	142671	CEL-383	Phase 1 Clinical	['Inflammatory bowel disease']	['Biological therapeutic', 'Intravenous formulation', 'Monoclonal antibody']	['Gastrointestinal']	
1100779	Circle Pharma	ancestor	98757	Wnt signaling/beta-catenin inhibitors (cancer), Circle/Pfizer	Discovery	['Cancer']	['Biological therapeutic', 'Immuno-oncology', 'Oral formulation', 'Parenteral formulation unspecified', 'Peptide']	['Cancer']	
1100779	Circle Pharma	ancestor	173124	CID-078	Preclinical	['Ovary tumor', 'Small-cell lung cancer']	['Biological therapeutic', 'Oral formulation', 'Peptide']	['Cancer']	
1100779	Circle Pharma	ancestor	113811	macrocyclic peptides targeting p53 (cancer), Circle Pharma	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1100779	Circle Pharma	ancestor	106063	macrocyclic peptides targeting cyclinA/cdk-2 (cancer), Circle Pharma	Preclinical	['Cancer', 'Small-cell lung cancer']	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Cancer']	
1100779	Circle Pharma	ancestor	106062	macrocyclic peptides targeting Mcl-1 (cancer), Circle Pharma	Discovery	['Cancer']	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Cancer']	
27293	Compugen	ancestor	69125	COM-701	Phase 2 Clinical	['Advanced solid tumor', 'Cancer', 'Endometrioid carcinoma', 'Fallopian tube cancer', 'Metastatic breast cancer', 'Metastatic colorectal cancer', 'Metastatic head and neck cancer', 'Metastatic liver cancer', 'Metastatic non small cell lung cancer', 'Metastatic ovary cancer', 'Multiple myeloma', 'Peritoneal tumor', 'Squamous cell carcinoma']	['Antibody fragment', 'Biological therapeutic', 'Immuno-oncology', 'Immunoglobulin G isotype antibody', 'Intravenous formulation', 'Monoclonal antibody humanized', 'Protein fusion']	['Immune', 'Cancer']	
27293	Compugen	ancestor	65492	CGEN-15001	Preclinical	['Autoimmune disease', 'Insulin dependent diabetes', 'Multiple sclerosis', 'Psoriasis', 'Rheumatoid arthritis']	['Antibody fragment', 'Biological therapeutic', 'Immuno-oncology', 'Immunoglobulin G isotype antibody', 'Parenteral formulation unspecified', 'Protein fusion']	['Immune', 'Hematologic', 'Endocrine/Metabolic', 'Dermatologic', 'Cancer']	
27293	Compugen	ancestor	148252	COM-503	Preclinical	['Cancer']	['Biological therapeutic', 'Human antibody therapy', 'Immuno-oncology', 'Systemic formulation unspecified']	['Cancer']	
27293	Compugen	ancestor	109958	bispecific/ multi-specific antibodies (cancer), MedImmune/ Compugen	Discovery	['Cancer']	['Biological therapeutic', 'Bispecific antibody', 'Multispecific antibody']	['Cancer']	
27293	Compugen	ancestor	106918	CGEN-15032 checkpoint inhibitor (cancer), Compugen	Preclinical	['Cancer']	['Antibody therapy', 'Biological therapeutic', 'Immuno-oncology', 'Parenteral formulation unspecified']	['Cancer']	
27293	Compugen	ancestor	104436	COM-902	Phase 1 Clinical	['Cancer', 'Colon tumor', 'Head and neck tumor', 'Lung tumor', 'Metastasis', 'Metastatic colorectal cancer', 'Multiple myeloma', 'Ovary tumor', 'Squamous cell carcinoma']	['Biological therapeutic', 'Immuno-oncology', 'Immunoglobulin G isotype antibody', 'Intravenous formulation', 'Monoclonal antibody human']	['Cancer']	
27293	Compugen	ancestor	97666	CGEN-XXXX checkpoint inhibitor (cancer), Compugen	No Development Reported	[]	['Biological therapeutic', 'Immuno-oncology', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Discovery
27293	Compugen	ancestor	97661	antibody drug conjugates (cancer), Compugen	No Development Reported	[]	['Antibody drug conjugate', 'Biological therapeutic']	['Cancer']	Discovery
27293	Compugen	ancestor	91597	CGEN-15052 checkpoint inhibitor (cancer), Compugen	No Development Reported	[]	['Antibody polyclonal', 'Biological therapeutic', 'Immuno-oncology', 'Parenteral formulation unspecified']	['Cancer']	Discovery
27293	Compugen	ancestor	89107	CGEN-15022 checkpoint inhibitor (cancer), Compugen/Bayer	Discontinued	[]	['Biological therapeutic', 'Immuno-oncology', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Discovery
27293	Compugen	ancestor	87587	CGEN-15049 checkpoint inhibitor (cancer), Compugen	No Development Reported	[]	['Biological therapeutic', 'Immuno-oncology', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Discovery
27293	Compugen	ancestor	86786	bapotulimab	No Development Reported	[]	['Antibody therapy', 'Biological therapeutic', 'Immuno-oncology', 'Intravenous formulation']	['Cancer']	Phase 1 Clinical
27293	Compugen	ancestor	77365	A-11, Compugen	No Development Reported	[]	['Biological therapeutic', 'Peptide']	['Cancer', 'Ocular']	Discovery
27293	Compugen	ancestor	75030	BL-7070	No Development Reported	[]	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Cardiovascular', 'Inflammatory']	Discovery
27293	Compugen	ancestor	75029	BL-7060	No Development Reported	[]	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Cardiovascular', 'Inflammatory']	Discovery
27293	Compugen	ancestor	70378	protein-protein interaction inhibitors (cancer), Compugen	No Development Reported	[]	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Cancer']	Discovery
27293	Compugen	ancestor	70376	CGEN-25068	No Development Reported	[]	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Immune']	Discovery
27293	Compugen	ancestor	69762	CGEN-973B	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Clinical
27293	Compugen	ancestor	69675	CGEN-913	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer', 'Inflammatory']	Discovery
27293	Compugen	ancestor	69674	CGEN-920	No Development Reported	[]	['Biological therapeutic', 'Parenteral formulation unspecified']	['Cancer', 'Inflammatory']	Discovery
27293	Compugen	ancestor	69670	CGEN-712	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Discovery
27293	Compugen	ancestor	69666	CGEN-791	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Discovery
27293	Compugen	ancestor	69664	CGEN-973A	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Clinical
27293	Compugen	ancestor	69652	CGEN-243	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer', 'Immune']	Clinical
27293	Compugen	ancestor	69638	Anti-CGEN-991 antibody (ovarian cancer), Compugen	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Discovery
27293	Compugen	ancestor	69618	Anti-CGEN-153 mAb (ovarian cancer), Compugen	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Cancer']	Discovery
1140964	Deep Genomics	ancestor	138131	oligonucleotide therapy (refractory gout), Deep Genomics	Discovery	['Gout']	['Biological therapeutic', 'Infusion', 'Intravenous formulation', 'Oligonucleotide']	['Inflammatory']	
1140964	Deep Genomics	ancestor	138130	oligonucleotide therapy (Parkinson's disease), Deep Genomics	Discovery	['Parkinsons disease']	['Biological therapeutic', 'Infusion', 'Intravenous formulation', 'Oligonucleotide']	['Neurology/Psychiatric']	
1140964	Deep Genomics	ancestor	138129	oligonucleotide therapy (Niemann-Pick type C disease), Deep Genomics	Discovery	['Niemann Pick disease type C']	['Biological therapeutic', 'Infusion', 'Intravenous formulation', 'Oligonucleotide']	['Endocrine/Metabolic']	
1140964	Deep Genomics	ancestor	138128	oligonucleotide therapy (frontotemporal dementia), Deep Genomics	Discovery	['Frontotemporal dementia']	['Biological therapeutic', 'Infusion', 'Intravenous formulation', 'Oligonucleotide']	['Neurology/Psychiatric']	
1140964	Deep Genomics	ancestor	138127	oligonucleotide therapy (pediatric epilepsy), Deep Genomics	Discovery	['Epilepsy']	['Biological therapeutic', 'Infusion', 'Intravenous formulation', 'Oligonucleotide']	['Neurology/Psychiatric']	
1140964	Deep Genomics	ancestor	119092	DG-12-P1	Preclinical	['Wilson disease']	['Biological therapeutic', 'Infusion', 'Intravenous formulation', 'Oligonucleotide']	['Gastrointestinal']	
1140964	Deep Genomics	ancestor	119268	undisclosed gene therapy (oligonucleotide, retinopathy), Deep Genomics	No Development Reported	[]	['Biological therapeutic', 'Oligonucleotide', 'Ophthalmic formulation']	['Ocular']	Discovery
1140964	Deep Genomics	ancestor	119267	DG-11-P1	No Development Reported	[]	['Biological therapeutic', 'Infusion', 'Intravenous formulation', 'Oligonucleotide']	['Endocrine/Metabolic']	Preclinical
1159823	Engine Biosciences	ancestor	123017	TDP-43 modulators (ALS), Engine Biosciences	Discovery	['Motor neurone disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1026417	e-Therapeutics	ancestor	97525	ETS-6200	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1026417	e-Therapeutics	ancestor	97524	ETS-2400	No Development Reported	[]	['Small molecule therapeutic']	['Cancer']	Discovery
1026417	e-Therapeutics	ancestor	97522	ETS-3100	No Development Reported	[]	['Small molecule therapeutic']	['Immune']	Discovery
1026417	e-Therapeutics	ancestor	97521	ETS-2300	No Development Reported	[]	['Small molecule therapeutic']	['Cancer']	Discovery
1026417	e-Therapeutics	ancestor	90032	dexanabinol (oral, cancer), e-Therapeutics	No Development Reported	[]	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	Phase 1 Clinical
1026417	e-Therapeutics	ancestor	87978	dexanabinol (oral formulation, cancer), e-Therapeutics	No Development Reported	[]	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	Discovery
1026417	e-Therapeutics	ancestor	63104	dexanabinol (intravenous, cancer), e-Therapeutics	No Development Reported	[]	['Infusion', 'Intravenous formulation', 'Small molecule therapeutic']	['Cancer']	Phase 1 Clinical
1026417	e-Therapeutics	ancestor	63101	ETX-1153b	No Development Reported	[]	['Drug combination', 'Intravenous formulation', 'Small molecule therapeutic']	['Infection']	Discovery
1026417	e-Therapeutics	ancestor	63087	nisin + miconazole (oral, Clostridium difficile infection), e-Therapeutics	No Development Reported	[]	['Antibiotic', 'Drug combination', 'Oral formulation', 'Small molecule therapeutic', 'Tablet formulation']	['Infection']	Discovery
1026417	e-Therapeutics	ancestor	63080	ETS-7211	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1026417	e-Therapeutics	ancestor	63077	ETS-6218	No Development Reported	[]	['Drug combination', 'Small molecule therapeutic', 'Systemic formulation unspecified']	['Musculoskeletal']	Phase 2 Clinical
1026417	e-Therapeutics	ancestor	63074	ETS-2123	No Development Reported	[]	['Small molecule therapeutic']	['Cancer']	Discovery
1026417	e-Therapeutics	ancestor	63072	ETX-6201	No Development Reported	[]	['Small molecule therapeutic']	['Ocular']	Discovery
1026417	e-Therapeutics	ancestor	63071	ETX-6765	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1026417	e-Therapeutics	ancestor	59126	ETX-6107	No Development Reported	[]	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Cardiovascular']	Phase 2 Clinical
1026417	e-Therapeutics	ancestor	59122	ETX-9101	No Development Reported	[]	['Drug combination', 'Oral formulation', 'Small molecule therapeutic']	['Respiratory']	Phase 3 Clinical
1026417	e-Therapeutics	ancestor	59076	tramadol (oral, depression), e-Therapeutics	No Development Reported	[]	['Oral controlled release formulation', 'Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	Phase 2 Clinical
1026417	e-Therapeutics	ancestor	56696	eTS-5203	No Development Reported	[]	['Small molecule therapeutic']	['Dermatologic']	Discovery
1026417	e-Therapeutics	ancestor	56694	anticancer agents, e-Therapeutics	No Development Reported	[]	['Small molecule therapeutic']	['Cancer']	Discovery
1026417	e-Therapeutics	ancestor	56692	antifungals, e-Therapeutics	No Development Reported	[]	['Small molecule therapeutic']	['Infection']	Discovery
1073911	Evaxion Biotech	ancestor	98225	Acinetobacter baumannii vaccine, Evaxion	Preclinical	['Acinetobacter baumannii infection']	['Biological therapeutic']	['Infection']	
1073911	Evaxion Biotech	ancestor	98223	EVX-B2	Preclinical	['Neisseria gonorrhoeae infection']	['Biological therapeutic']	['Infection', 'Respiratory']	
1073911	Evaxion Biotech	ancestor	98222	EVX-B3	Discovery	['Unidentified indication']	['Biological therapeutic']	['Infection', 'Respiratory']	
1073911	Evaxion Biotech	ancestor	82883	EVX-B1	Preclinical	['Skin infection', 'Staphylococcus aureus infection']	['Biological therapeutic', 'Peptide']	['Infection']	
1073911	Evaxion Biotech	ancestor	146157	EVX-V1	Preclinical	['Cytomegalovirus infection', 'Viral infection']	['Biological therapeutic', 'Injectable formulation', 'Parenteral formulation unspecified']	['Infection']	
1073911	Evaxion Biotech	ancestor	115666	EVX-03	Preclinical	['Cancer', 'Melanoma', 'Non-small-cell lung cancer', 'Solid tumor']	['Biological therapeutic', 'Peptide']	['Cancer']	
1073911	Evaxion Biotech	ancestor	109665	EVX-01	Phase 2 Clinical	['Bladder cancer', 'Metastatic non small cell lung cancer', 'Metastatic renal cancer', 'Stage III melanoma', 'Stage IV melanoma']	['Biological therapeutic', 'Intramuscular formulation', 'Intraperitoneal formulation', 'Liposome formulation', 'Peptide', 'Tumor antigen therapeutic']	['Cancer']	
1073911	Evaxion Biotech	ancestor	109664	EVX-02	Phase 2 Clinical	['Cancer', 'Stage III melanoma', 'Stage IV melanoma']	['Biological therapeutic', 'Intramuscular formulation', 'Peptide']	['Cancer']	
1073911	Evaxion Biotech	ancestor	109663	EVX-B4	Preclinical	['Chronic obstructive pulmonary disease']	['Biological therapeutic', 'Peptide']	['Respiratory']	
1073911	Evaxion Biotech	ancestor	100867	MVA-BN (MRSA), Bavarian Nordic/ Evaxion	Discovery	['MRSA infection']	['Biological therapeutic', 'Virus recombinant']	['Infection']	
1073911	Evaxion Biotech	ancestor	98242	Staphylococcus aureus mAb, Evaxion	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Infection']	Discovery
1102412	Exscientia	ancestor	168087	SARS-CoV-2 MPro inhibitors (COVID-19), Exscientia	Discovery	['Coronavirus disease 19 infection']	['Small molecule therapeutic']	['Infection']	
1102412	Exscientia	ancestor	142450	EXS-617	Phase 2 Clinical	['Advanced solid tumor', 'Metastatic breast cancer', 'Metastatic colorectal cancer', 'Metastatic head and neck cancer', 'Metastatic non small cell lung cancer', 'Metastatic ovary cancer', 'Metastatic pancreas cancer', 'Pancreatic adenocarcinoma', 'Squamous cell carcinoma']	['Oral formulation', 'Small molecule therapeutic', 'Tablet formulation']	['Cancer']	
1102412	Exscientia	ancestor	140425	NLRP3 inflammasome inhibitor (Alzheimers disease), Exscientia/University of Oxford	Discovery	['Alzheimers disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1102412	Exscientia	ancestor	134192	DSP-0038	Phase 1 Clinical	['Alzheimers disease', 'Psychiatric disorder']	['Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	
1102412	Exscientia	ancestor	121601	DSP-1181	Phase 1 Clinical	['Obsessive compulsive disorder']	['Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	
1102412	Exscientia	ancestor	106173	EXS-21546	Phase 1 Clinical	['Cancer', 'Solid tumor']	['Capsule formulation', 'Immuno-oncology', 'Oral formulation', 'Oral suspension formulation', 'Small molecule therapeutic']	['Cancer']	
1102412	Exscientia	ancestor	106136	dual A2aR checkpoint inhibitor/CD73 checkpoint inhibitor (cancer), Ex scientia/Evotec	Preclinical	['Cancer']	['Immuno-oncology', 'Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1102412	Exscientia	ancestor	101780	multi-target small molecules (cancer), ex scientia/ Evotec	Discovery	['Cancer']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1102412	Exscientia	ancestor	93441	dopamine D4 inverse agonists (cognitive disorders), Ex scientia	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1102412	Exscientia	ancestor	93439	multi-target small molecules (psychiatric disorder), EX scientia/Sunovion	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Preclinical
1102412	Exscientia	ancestor	115552	chronic obstructive pulmonary disease therapy, Exscientia/GSK	No Development Reported	[]	['Small molecule therapeutic']	['Respiratory']	Preclinical
1155639	Finch Therapeutics	ancestor	127176	FIN-525	Preclinical	['Crohns disease']	['Biological therapeutic', 'Freeze drying', 'Natural product', 'Oral formulation']	['Gastrointestinal']	
1155639	Finch Therapeutics	ancestor	127175	FIN-211	Preclinical	['Autism', 'Gastrointestinal disease']	['Biological therapeutic', 'Freeze drying', 'Natural product', 'Oral formulation']	['Gastrointestinal', 'Neurology/Psychiatric']	
1155639	Finch Therapeutics	ancestor	116378	microbiome-derived therapeutic (oral capsule, obesity), Brigham & Women's Hospital/Finch Therapeutics	Phase 2 Clinical	['Obesity']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Other/Miscellaneous']	
1155639	Finch Therapeutics	ancestor	108982	CP-101, Finch Therapeutics Group	Preclinical	['Hepatitis B virus infection', 'Ulcerative colitis']	['Biological therapeutic', 'Capsule formulation', 'Natural product', 'Oral formulation']	['Infection', 'Neurology/Psychiatric', 'Gastrointestinal']	
1155639	Finch Therapeutics	ancestor	105515	FIN-524	Preclinical	['Inflammatory bowel disease', 'Ulcerative colitis']	['Biological therapeutic', 'Natural product', 'Oral formulation']	['Gastrointestinal']	
1138780	Finch Therapeutics Inc	subsidiary	125691	FIN-603	Preclinical	['Cancer', 'Solid tumor']	['Parenteral formulation unspecified', 'Small molecule therapeutic']	['Cancer']	
1138780	Finch Therapeutics Inc	subsidiary	125685	FIN-215	Discovery	['Autism']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1138780	Finch Therapeutics Inc	subsidiary	105427	FIN-403	No Development Reported	[]	['Biological therapeutic', 'Capsule formulation', 'Oral controlled release formulation', 'Oral formulation']	['Infection']	Clinical
1189253	Frontier Medicines	ancestor	145329	FMC-376	Preclinical	['Cancer', 'Colorectal tumor', 'Non-small-cell lung cancer', 'Pancreas tumor']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1115276	Gritstone Oncology	ancestor	150924	GRT-R918	Phase 1 Clinical	['Coronavirus disease 19 infection']	['Biological therapeutic', 'Intramuscular formulation', 'Oligonucleotide']	['Infection']	
1115276	Gritstone Oncology	ancestor	149002	GRT-R914	Phase 1 Clinical	['Coronavirus disease 19 infection']	['Biological therapeutic', 'Intramuscular formulation', 'Oligonucleotide']	['Infection']	
1115276	Gritstone Oncology	ancestor	147200	GRT-R912	Phase 1 Clinical	['Coronavirus disease 19 infection']	['Biological therapeutic', 'Intramuscular formulation', 'Oligonucleotide']	['Infection']	
1115276	Gritstone Oncology	ancestor	134090	HIV vaccine (HIV infection), Gritstone Oncology/Gilead Sciences	Preclinical	['HIV infection']	['Biological therapeutic']	['Infection']	
1115276	Gritstone Oncology	ancestor	130064	CORAL (samRNA vaccine, COVID-19), Gritstone Oncology	Phase 1 Clinical	['Coronavirus disease 19 infection']	['Biological therapeutic', 'Intramuscular formulation', 'Oligonucleotide']	['Infection']	
1115276	Gritstone Oncology	ancestor	113818	bispecific antibody program (BiSAb/EDGE/TCR-mimetic, solid tumor), Gritstone Oncology	Preclinical	['Solid tumor']	['Biological therapeutic', 'Bispecific T cell engager antibody', 'Immuno-oncology', 'Parenteral formulation unspecified']	['Cancer']	
1115276	Gritstone Oncology	ancestor	107761	GRANITE-001	Phase 3 Clinical	['Adenocarcinoma', 'Advanced solid tumor', 'Colorectal tumor', 'Esophagus tumor', 'Metastatic bladder cancer', 'Metastatic colorectal cancer', 'Metastatic non small cell lung cancer', 'Stomach tumor']	['Biological therapeutic', 'Intramuscular formulation', 'Nanoparticle formulation injectable', 'Oligonucleotide', 'Tumor antigen therapeutic']	['Cancer']	
1115276	Gritstone Oncology	ancestor	100585	SLATE-001	Phase 2 Clinical	['Advanced solid tumor', 'Cancer', 'Metastatic colorectal cancer', 'Metastatic non small cell lung cancer', 'Metastatic pancreas cancer', 'Pancreatic ductal adenocarcinoma']	['Biological therapeutic', 'Intramuscular formulation', 'Nanoparticle formulation injectable', 'Oligonucleotide', 'Tumor antigen therapeutic']	['Cancer']	
1115276	Gritstone Oncology	ancestor	103469	ZVexNeo	No Development Reported	[]	['Biological therapeutic', 'Tumor antigen therapeutic']	['Cancer']	Discovery
1108263	Healx	ancestor	30614	gaboxadol	Phase 2 Clinical	['Fragile X syndrome']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	
1108263	Healx	ancestor	148873	nitroxoline (neurofibromatosis type 1-plexiform neurofibroma), Healx	Preclinical	['Neurofibromatosis type I']	['Small molecule therapeutic']	['Cancer']	
1108263	Healx	ancestor	148871	drug candidate (neurofibromatosis type 1-cutaneous neurofibroma), Healx	Preclinical	['Neurofibromatosis type I']	['Small molecule therapeutic']	['Cancer']	
1108263	Healx	ancestor	148870	drug candidate (SARS-CoV-2 infection), Healx	Preclinical	['Coronavirus disease 19 infection']	['Small molecule therapeutic']	['Infection']	
1108263	Healx	ancestor	148869	drug candidate (Angelman syndrome), Healx	Preclinical	['Angelman syndrome']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1108263	Healx	ancestor	148863	drug candidate (bone disease), Healx	Preclinical	['Bone disease']	['Small molecule therapeutic']	['Musculoskeletal']	
1108263	Healx	ancestor	148862	drug candidate (Healnet, autosomal recessive polycystic kidney disease), Healx	Preclinical	['Autosomal recessive polycystic kidney disease']	['Small molecule therapeutic']	['Genitourinary/Sexual Function']	
1108263	Healx	ancestor	148861	drug candidate (neuromuscular diseases), Healx	Preclinical	['Neuromuscular disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1108263	Healx	ancestor	148839	autosomal dominant polycystic kidney disease therapy, Healx	Preclinical	['Autosomal dominant polycystic kidney disease']	[]	['Genitourinary/Sexual Function']	
1108263	Healx	ancestor	148587	drug candidate (renal disease), Healx	Preclinical	['Renal disease']	['Small molecule therapeutic']	['Genitourinary/Sexual Function']	
1108263	Healx	ancestor	148586	drug candidate (liver disease), Healx	Preclinical	['Liver disease']	['Small molecule therapeutic']	['Gastrointestinal']	
1108263	Healx	ancestor	148585	drug candidate (chronic pancreatitis), Healx	Preclinical	['Pancreatitis']	['Small molecule therapeutic']	['Gastrointestinal']	
1108263	Healx	ancestor	148584	drug candidate (facioscapulohumeral muscular dystrophy), Healx	Preclinical	['Facioscapulohumeral muscular dystrophy']	['Small molecule therapeutic']	['Musculoskeletal']	
1108263	Healx	ancestor	148048	HLX-0205	Preclinical	['Fragile X syndrome']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1108263	Healx	ancestor	147438	ibudilast (fragile X syndrome), Healx	Discovery	['Fragile X syndrome']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1108263	Healx	ancestor	131766	HLX-0201	Preclinical	['Fragile X syndrome']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	
1108263	Healx	ancestor	97439	NGLY1 gene modulators (congenital disorder of deglycosylation), Healx	No Development Reported	[]	['Small molecule therapeutic']	['Endocrine/Metabolic']	Discovery
1046215	Immuneering	ancestor	145705	IMM-ALL-01	Discovery	['Alzheimers disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1046215	Immuneering	ancestor	145704	IMM-ALL-03	Discovery	['Alzheimers disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1046215	Immuneering	ancestor	145553	RAS induction pathway modulator (cancer), Immuneering Corp	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1046215	Immuneering	ancestor	145283	allosteric PI3K-alpha inhibitors (cancer), Immuneering Corp	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1046215	Immuneering	ancestor	145233	covalent MEK inhibitor (cancer), Immuneering Corp	Preclinical	['Cancer']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Cancer']	
1046215	Immuneering	ancestor	143964	IMM-6-415	Preclinical	['Solid tumor']	['Small molecule therapeutic']	['Cancer']	
1046215	Immuneering	ancestor	129754	IMM-1811900	Discovery	['Cancer', 'Colorectal tumor', 'Lung tumor', 'Pancreas tumor']	['Small molecule therapeutic']	['Cancer']	
1046215	Immuneering	ancestor	129753	IMM-2019611	Preclinical	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1046215	Immuneering	ancestor	129752	IMM-1-104	Phase 2 Clinical	['Advanced solid tumor', 'Cancer', 'Lung tumor', 'Metastatic colorectal cancer', 'Metastatic non small cell lung cancer', 'Pancreatic ductal adenocarcinoma', 'Stage IV melanoma']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1209718	ImmunoScape	ancestor	142320	TCR T-cell therapy (cancer), ImmunoScape/PureMHC	Discovery	['Cancer', 'Colorectal tumor', 'Lung tumor']	['Biological therapeutic', 'Immuno-oncology', 'Infusion', 'Intravenous formulation', 'Protein recombinant', 'T-lymphocyte', 'T-lymphocyte cell therapy']	['Cancer']	
1123826	Insilico Medicine	ancestor	172400	ISM-5939	Preclinical	['Cancer', 'Hypophosphatasia', 'Solid tumor']	['Oral formulation', 'Small molecule therapeutic']	['Cancer', 'Endocrine/Metabolic']	
1123826	Insilico Medicine	ancestor	172390	KAT6 inhibitor (ER+/HER2- breast cancer), Insilico Medicine	Preclinical	['Breast tumor']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1123826	Insilico Medicine	ancestor	172389	TEAD modulator (solid tumor), Insilico Medicine	Preclinical	['Solid tumor']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Cancer']	
1123826	Insilico Medicine	ancestor	172386	cMYC modulator (solid tumor), Insilico Medicine	Discovery	['Solid tumor']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Cancer']	
1123826	Insilico Medicine	ancestor	172312	INS018-055 (inhalant formulation), Insilico Medicine	Preclinical	['Idiopathic pulmonary fibrosis']	['Inhalant formulation', 'Small molecule therapeutic']	['Respiratory']	
1123826	Insilico Medicine	ancestor	165943	ISM-4312A	Preclinical	['Cancer', 'Solid tumor']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1123826	Insilico Medicine	ancestor	163103	ISM-6466A	Preclinical	['Cancer', 'Solid tumor']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Cancer']	
1123826	Insilico Medicine	ancestor	147006	ISM-3412	Preclinical	['Cancer']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1123826	Insilico Medicine	ancestor	145587	ISM-3312	Phase 1 Clinical	['Coronavirus disease 19 infection']	['Oral formulation', 'Small molecule therapeutic']	['Infection']	
1123826	Insilico Medicine	ancestor	143122	ISM012-042	Preclinical	['Inflammatory bowel disease']	['Oral formulation', 'Small molecule therapeutic']	['Gastrointestinal']	
1123826	Insilico Medicine	ancestor	143121	ISM-4808	Preclinical	['Anemia', 'End stage renal disease']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Genitourinary/Sexual Function', 'Hematologic']	
1123826	Insilico Medicine	ancestor	141751	ISM004-1057D	Phase 1 Clinical	['Acute myelogenous leukemia', 'Cancer', 'Non-Hodgkin lymphoma', 'Solid tumor']	['Immuno-oncology', 'Small molecule therapeutic', 'Systemic formulation unspecified']	['Cancer', 'Genitourinary/Sexual Function']	
1123826	Insilico Medicine	ancestor	140030	INS018-055	Phase 2 Clinical	['Idiopathic pulmonary fibrosis', 'Renal fibrosis']	['Capsule formulation', 'Intravenous formulation', 'Oral formulation', 'Small molecule therapeutic']	['Genitourinary/Sexual Function', 'Respiratory']	
1123826	Insilico Medicine	ancestor	166424	ISM-3091	Phase 1 Clinical	['Advanced solid tumor', 'Metastatic breast cancer', 'Metastatic ovary cancer', 'Metastatic prostate cancer']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1123826	Insilico Medicine	ancestor	144434	GB-701	No Development Reported	[]	['Ophthalmic formulation', 'Small molecule therapeutic', 'Systemic formulation unspecified']	['Ocular']	Preclinical
1123826	Insilico Medicine	ancestor	136505	therapeutic program (hematological malignancy), Insilico Medicine/BioNova Pharmaceuticals	No Development Reported	[]	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Cancer']	Discovery
1123826	Insilico Medicine	ancestor	111726	CLK inhibitor (Duchenne muscular dystrophy/ rare diseases therapy/cancer), Consortium/A2A/Insilico	No Development Reported	[]	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Musculoskeletal', 'Cancer']	Preclinical
1123826	Insilico Medicine	ancestor	109279	JAI-001	No Development Reported	[]	['Small molecule therapeutic']	['Other/Miscellaneous']	Preclinical
1106466	Lantern Pharma	ancestor	98907	irofulven-2	Phase 1 Clinical	['Advanced solid tumor', 'Bladder cancer', 'Brain tumor', 'Breast tumor', 'Central nervous system tumor', 'Glioblastoma', 'Glioma', 'Lung tumor', 'Metastasis', 'Metastatic brain cancer', 'Metastatic pancreas cancer', 'Non-small-cell lung cancer', 'Ovary tumor', 'Pancreas tumor', 'Prostate tumor', 'Solid tumor']	['Prodrug', 'Small molecule therapeutic']	['Cancer']	
1106466	Lantern Pharma	ancestor	8934	irofulven	Phase 2 Clinical	['Hormone refractory prostate cancer']	['Infusion', 'Intravenous formulation', 'Small molecule therapeutic']	['Cancer']	
1106466	Lantern Pharma	ancestor	135986	LP-A18	Discovery	['Solid tumor']	['Antibody drug conjugate', 'Biological therapeutic', 'Parenteral formulation unspecified']	['Cancer']	
1106466	Lantern Pharma	ancestor	131278	LP-284	Preclinical	['B-cell lymphoma', 'Cancer', 'Hematological neoplasm', 'High grade B-cell lymphoma', 'Mantle cell lymphoma', 'Non-Hodgkin lymphoma']	['Intravenous formulation', 'Small molecule therapeutic']	['Cancer']	
1106466	Lantern Pharma	ancestor	13071	dimesna	Phase 2 Clinical	['Adenocarcinoma', 'Metastatic non small cell lung cancer', 'Non-small-cell lung cancer']	['Infusion', 'Intravenous formulation', 'Small molecule therapeutic']	['Toxicity/Intoxication', 'Cancer', 'Gastrointestinal']	
1106466	Lantern Pharma	ancestor	104788	LP-400	Discontinued	[]	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Cancer']	Phase 2 Clinical
1187485	Modulus Discovery	ancestor	171904	MOD-000001	Preclinical	['Food hypersensitivity', 'Immediate type hypersensitivity']	['Oral formulation', 'Small molecule therapeutic']	['Immune']	
1187485	Modulus Discovery	ancestor	171590	MOD-B	Preclinical	['Allergy', 'Inflammatory disease']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Immune', 'Inflammatory']	
1187485	Modulus Discovery	ancestor	146417	MOD-06051	Preclinical	['Vasculitis']	['Small molecule therapeutic']	['Cardiovascular']	
1238098	Neuron23	ancestor	163285	anti-Trop2 antibody-drug conjugate (TORPEDO, gastric carcinoma), Peak Bio/Dren Bio/3T Biosciences/Neuron23/Aarvik Therapeutics	Preclinical	['Stomach tumor']	['Antibody drug conjugate', 'Biological therapeutic', 'Monoclonal antibody conjugated', 'Toxin']	['Cancer']	
1238098	Neuron23	ancestor	155283	undisclosed drug target (amyotrophic lateral sclerosis), Neuron23 Inc	Discovery	['Motor neurone disease']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1238098	Neuron23	ancestor	152144	NEU-411	Preclinical	['Parkinsons disease']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1238098	Neuron23	ancestor	142928	NEU-723	Phase 1 Clinical	['Parkinsons disease']	['Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	
1238098	Neuron23	ancestor	131144	TYK2 inhibitor (brain penetrant, systemic inflammation/neuritis), Neuron23	Preclinical	['Inflammatory disease', 'Multiple sclerosis', 'Neuritis']	['Small molecule therapeutic']	['Immune', 'Inflammatory', 'Neurology/Psychiatric']	
1154607	Peptilogics	ancestor	148260	undisclosed epigenetic target therapeutic (metastatic breast cancer), EpiAxis Therapeutics/Peptilogics	Discovery	['Metastatic breast cancer']	['Small molecule therapeutic']	['Cancer']	
1154607	Peptilogics	ancestor	141391	PLG-0206-A	Preclinical	['Joint disease']	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Musculoskeletal']	
1154607	Peptilogics	ancestor	140694	PLGAI-04	Discovery	['Cancer']	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Cancer']	
1154607	Peptilogics	ancestor	140693	PLGAI-03	Discovery	['Cancer']	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Cancer']	
1154607	Peptilogics	ancestor	140692	PLGAI-02	Discovery	['Genetic disorder']	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Other/Miscellaneous']	
1154607	Peptilogics	ancestor	139828	PLG-0301	Preclinical	['Bacterial infection', 'Cystic fibrosis', 'Lung infection', 'Multidrug resistant infection']	['Biological therapeutic', 'Parenteral formulation unspecified', 'Peptide']	['Respiratory', 'Infection']	
1154607	Peptilogics	ancestor	110063	PLG-0206	Phase 1 Clinical	['Bacterial infection', 'Cystic fibrosis', 'Joint infection', 'Lung infection', 'Multidrug resistant infection', 'Staphylococcus aureus infection']	['Biological therapeutic', 'Intravenous formulation', 'Liquid irrigation formulation', 'Local formulation unspecified', 'Peptide']	['Respiratory', 'Infection']	
1096979	Recursion Pharmaceuticals	ancestor	93336	REC-994	Phase 2 Clinical	['Hemangioma']	['Oral formulation', 'Small molecule therapeutic', 'Tablet formulation']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	64087	REC-4881	Phase 2 Clinical	['Advanced solid tumor', 'Familial adenomatous polyposis', 'Hepatocellular carcinoma', 'Metastatic colorectal cancer', 'Ovary tumor', 'Solid tumor']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Cancer', 'Gastrointestinal']	
1096979	Recursion Pharmaceuticals	ancestor	159884	targeted delta immunotherapy (cancer), Recursion Pharmaceuticals	Preclinical	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	150617	REC-64151	Preclinical	['Cancer', 'Non-small-cell lung cancer']	['Small molecule therapeutic']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	150479	RBM-39	Preclinical	['Ovary tumor']	['Small molecule therapeutic']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	150478	targeted beta immunotherapy (cancer), Recursion Pharmaceuticals	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	150477	drug candidate (cancer), Recursion Pharmaceuticals	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	150461	drug candidate (MYC driven cancers), Recursion Pharmaceuticals	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	150307	REC-648918	Preclinical	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	134058	REC-163964	Phase 1 Clinical	['Clostridium difficile infection']	['Oral formulation', 'Small molecule therapeutic']	['Infection']	
1096979	Recursion Pharmaceuticals	ancestor	106641	NF2 gene modulator (neurofibromatosis type-2), Recursion	Phase 1 Clinical	['Neurofibromatosis type II']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	93343	NIPBL gene modulator (Cornelia de Lange syndrome), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	93342	repurposed therapeutics (juvenile osteoporosis), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Musculoskeletal']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	93340	RPS10 gene modulator (diamond blackfan anemia), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Hematologic']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	93338	repurposed therapeutics (Rett syndrome), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	53085	REC-2282	Phase 3 Clinical	['Neurofibromatosis type II']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1096979	Recursion Pharmaceuticals	ancestor	122828	REC-65075	No Development Reported	[]	['Small molecule therapeutic']	['Cardiovascular']	Preclinical
1096979	Recursion Pharmaceuticals	ancestor	12032	ruboxistaurin	Discontinued	[]	['CNS formulation', 'Oral formulation', 'Small molecule therapeutic', 'Tablet formulation']	['Neurology/Psychiatric', 'Genitourinary/Sexual Function', 'Endocrine/Metabolic', 'Ocular', 'Cardiovascular']	Pre-registration
1096979	Recursion Pharmaceuticals	ancestor	110545	REC-0000067	No Development Reported	[]	['Small molecule therapeutic']	['Endocrine/Metabolic']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	106649	RPS6KA3 gene modulator (Coffin-Lowry syndrome), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Other/Miscellaneous']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	106648	KMT2D gene modulator (Kabuki syndrome), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Other/Miscellaneous']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	106647	repurposed therapeutics (Limb-Girdle muscular dystrophy), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Musculoskeletal']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	106646	SMN1 gene modulator (X-linked infantile spinal muscular atrophy), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	106644	STK11 gene modulator (Peutz-Jeghers syndrome), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Gastrointestinal']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	106642	repurposed therapeutics (metachromatic leukodystrophy), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	106640	SMN1 gene modulators (spinal muscular atrophy), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1096979	Recursion Pharmaceuticals	ancestor	106639	ATM serine/threonine kinase gene modulators (ataxia telangiectasia), Recursion	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1129791	Relay Therapeutics	ancestor	165487	ER-alpha degrader (breast cancer), Relay Therapeutics/EQRx	Preclinical	['Metastatic breast cancer']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1129791	Relay Therapeutics	ancestor	147557	RLY-2139	Preclinical	['Breast tumor']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1129791	Relay Therapeutics	ancestor	146209	RLY-5836	Phase 1 Clinical	['Advanced solid tumor', 'Breast tumor', 'Metastatic breast cancer']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1129791	Relay Therapeutics	ancestor	131581	genetic diseases program, Relay Therapeutics	Preclinical	['Genetic disorder']	['Small molecule therapeutic']	['Other/Miscellaneous']	
1129791	Relay Therapeutics	ancestor	129881	RLY-2608	Phase 1 Clinical	['Advanced solid tumor', 'Metastatic breast cancer', 'Metastatic head and neck cancer', 'Metastatic ovary cancer', 'Squamous cell carcinoma', 'Uterine cervix tumor']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1129791	Relay Therapeutics	ancestor	124982	lirafugratinib hydrochloride	Phase 2 Clinical	['Advanced solid tumor', 'Cholangiocarcinoma', 'Endometrioid carcinoma', 'Metastatic breast cancer', 'Metastatic stomach cancer']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1129791	Relay Therapeutics	ancestor	121727	RLY-1971	Phase 1 Clinical	['Advanced solid tumor', 'Metastatic colorectal cancer', 'Metastatic non small cell lung cancer']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic', 'Tablet formulation']	['Cancer']	
1129791	Relay Therapeutics	ancestor	114090	RTX-2	Discovery	['Cholangiocarcinoma']	['Small molecule therapeutic']	['Cancer']	
1129791	Relay Therapeutics	ancestor	118700	STING antagonists (undisclosed indication), Merck/Celgene/Relay Therapeutics	No Development Reported	[]	['Small molecule therapeutic']	['Unknown']	Preclinical
1023065	Schrödinger	ancestor	163383	AJ1-10502	Preclinical	['Myeloproliferative disorder']	['Small molecule therapeutic']	['Hematologic']	
1023065	Schrödinger	ancestor	160423	LRRK2 inhibitor (neurodegenerative diseases/parkinson disease), Schrodinger	Discovery	['Neurodegenerative disease', 'Parkinsons disease']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1023065	Schrödinger	ancestor	148677	D-amino acid oxidase inhibitors (schizophrenia), Charles River/Schrodinger	Preclinical	['Schizophrenia']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1023065	Schrödinger	ancestor	142334	SOS1 / KRAS (KRAS -driven cancer), Schrondinger	Preclinical	['Adrenal gland tumor']	['Small molecule therapeutic']	['Cancer']	
1023065	Schrödinger	ancestor	142069	Undisclosed therapeutic (cancer),Schrödinger LLC/Bristol-Myers Squibb Co	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1023065	Schrödinger	ancestor	140266	HIF-2a modulator (renal cell carcinoma), Schrödinger/Bristol-Myers Squibb	Discovery	['Renal cell carcinoma']	['Small molecule therapeutic']	['Cancer']	
1023065	Schrödinger	ancestor	136728	4’-phosphopantetheinyl transferase inhibitors (mycobacterium tuberculosis infection), Weill Cornell Medicine/University of North Carolina at Chapel Hill/Texas A&M University/Evotec/Schrodinger	Preclinical	['Mycobacterium tuberculosis infection']	['Antibiotic', 'Small molecule therapeutic']	['Infection']	
1023065	Schrödinger	ancestor	136450	SGR-3515	Preclinical	['Gynecological disorder', 'Solid tumor']	['Small molecule therapeutic']	['Cancer', 'Genitourinary/Sexual Function']	
1023065	Schrödinger	ancestor	132234	USP7 inhibitors (acute myeloid leukemia/multiple myeloma), Schrodinger/WuXi AppTec	Preclinical	['Acute myelogenous leukemia', 'Multiple myeloma']	['Small molecule therapeutic']	['Cancer']	
1023065	Schrödinger	ancestor	128326	SGR-1505	Phase 1 Clinical	['B-cell lymphoma', 'Burkitts lymphoma', 'Chronic lymphocytic leukemia', 'Diffuse large B-cell lymphoma', 'Follicle center lymphoma', 'High grade B-cell lymphoma', 'Lymphoplasmacytic lymphoma', 'Mantle cell lymphoma', 'Marginal zone B-cell lymphoma', 'Non-Hodgkin lymphoma', 'Primary mediastinal large B-cell lymphoma', 'Splenic marginal zone lymphoma']	['Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1023065	Schrödinger	ancestor	126225	SDGR-1	Phase 1 Clinical	['Acute myelogenous leukemia', 'Adenocarcinoma', 'Advanced solid tumor', 'Esophagus tumor', 'Hematological neoplasm', 'Lung tumor', 'Metastatic brain cancer', 'Metastatic non small cell lung cancer', 'Myelodysplastic syndrome', 'Solid tumor']	['CNS formulation', 'Oral formulation', 'Small molecule therapeutic']	['Cancer']	
1023065	Schrödinger	ancestor	115799	XPC-6444	Preclinical	['Epilepsy', 'Seizure disorder']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1023065	Schrödinger	ancestor	113866	Hsp 90 inhibitors (fungal infection), Bright Angel/ Schrödinger	Discovery	['Fungal infection']	['Small molecule therapeutic']	['Infection']	
1023065	Schrödinger	ancestor	94868	TAK-279	Phase 2 Clinical	['Psoriasis', 'Psoriatic arthritis']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Cancer', 'Dermatologic', 'Immune', 'Inflammatory']	
1023065	Schrödinger	ancestor	94740	falcipain-2 and 3 inhibitors (malaria), University of Mississippi/University of California/Loma Linda University/Schrodinger Inc	No Development Reported	[]	['Small molecule therapeutic']	['Infection']	Discovery
1023065	Schrödinger	ancestor	92796	PDGFR-beta inhibitors (cancer), Schrodinger/ProQinase	No Development Reported	[]	['Small molecule therapeutic']	['Cancer']	Discovery
1023065	Schrödinger	ancestor	70979	p53-MDM2 protein interaction inhibitors (cancer), The Lee Moffitt Cancer Center and Research Institute	No Development Reported	[]	['Small molecule therapeutic']	['Cancer']	Discovery
1023065	Schrödinger	ancestor	69178	protein kinase G inhibitors (pain), Schrodinger/Columbia University	No Development Reported	[]	['Small molecule therapeutic']	['Neurology/Psychiatric']	Discovery
1023065	Schrödinger	ancestor	112424	CSF-1R inhibitors (cancer), Integral BioSciences/Medivation Inc/Fundacion Ciencia Para La Vida/Schrodinger Inc	No Development Reported	[]	['Small molecule therapeutic']	['Cancer']	Preclinical
1114113	XTAL BioStructures	subsidiary	119928	PHGDH inhibitors (cancer), Takeda Pharmaceutical/Xtal Biostructures	Discovery	['Cancer']	['Small molecule therapeutic']	['Cancer']	
1161011	Standigm	ancestor	168464	DNAJB1-PRKACA inhibitors (hepatocellular carcinoma), Standigm	Preclinical	['Hepatocellular carcinoma']	['Small molecule therapeutic']	['Cancer']	
1161011	Standigm	ancestor	126130	repurposed drug candidates (NASH), Standigm	Preclinical	['Non-alcoholic steatohepatitis']	['Small molecule therapeutic']	['Gastrointestinal']	
1161011	Standigm	ancestor	123719	LRRK2 inhibitors (Parkinson’s disease), Standigm	Preclinical	['Parkinsons disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	162863	Parkinson's disease program 2, Verge Genomics	Discovery	['Parkinsons disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	162847	Parkinson's disease program 3, Verge Genomics	Discovery	['Parkinsons disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	160844	progressive supranuclear palsy program, Verge Genomics	Discovery	['Progressive supranuclear palsy']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	160843	undisclosed drug target schizophrenia program, Verge Genomics	Discovery	['Schizophrenia']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	124765	dementia program (Lewy body dementia/corticobasal degeneration/Pick's disease), Verge Genomics	Discovery	['Dementia', 'Lewy body dementia']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	124762	frontotemporal dementia therapy, Verge Genomics	Discovery	['Frontotemporal dementia']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	124761	Parkinson's disease program 1, Verge Genomics	Discovery	['Parkinsons disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	124760	amyotrophic lateral sclerosis therapy, Verge Genomics/ Eli Lilly	Discovery	['Motor neurone disease']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	124758	VRG-50635	Phase 1 Clinical	['Motor neurone disease']	['Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric']	
1146473	Verge Genomics	ancestor	124757	PIKfyve inhibitors (oral, COVID19), Verge Genomics	Preclinical	['Coronavirus disease 19 infection']	['Oral formulation', 'Small molecule therapeutic']	['Infection']	
1212881	Alto Neuroscience	ancestor	52605	rislenemdaz	Phase 2 Clinical	['Major depressive disorder', 'Post traumatic stress disorder']	['Capsule formulation', 'Oral formulation', 'Small molecule therapeutic']	['Neurology/Psychiatric', 'Cardiovascular']	
1212881	Alto Neuroscience	ancestor	170285	dopamine pathway modulator (drug combination, neuropsychiatric/ neurodegenerative disease), Alto Neuroscience	Phase 1 Clinical	['Neurodegenerative disease', 'Psychiatric disorder']	['Drug combination', 'Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1212881	Alto Neuroscience	ancestor	166003	100's series novel combination (neurological disorder/psychiatric disorder), Alto neurosciences	Phase 1 Clinical	['Neurological disease', 'Psychiatric disorder']	['Drug combination', 'Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1212881	Alto Neuroscience	ancestor	165787	ALTO-101	Phase 1 Clinical	['Neurodegenerative disease', 'Psychiatric disorder']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1212881	Alto Neuroscience	ancestor	165786	ALTO-203	Phase 1 Clinical	['Neurodegenerative disease', 'Psychiatric disorder']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1212881	Alto Neuroscience	ancestor	162903	ALTO-104	Phase 1 Clinical	['Psychiatric disorder']	['Small molecule therapeutic', 'Systemic formulation unspecified']	['Neurology/Psychiatric']	
1212881	Alto Neuroscience	ancestor	162063	ALTO-103	Phase 1 Clinical	['Psychiatric disorder']	['Small molecule therapeutic']	['Neurology/Psychiatric']	
1212881	Alto Neuroscience	ancestor	154323	ALTO-102	Discovery	['Unidentified indication']	['Small molecule therapeutic']	['Unknown']	
1212881	Alto Neuroscience	ancestor	146642	ALTO-300	Phase 2 Clinical	['Major depressive disorder']	['Oral formulation', 'Small molecule therapeutic', 'Tablet formulation']	['Neurology/Psychiatric']	
1212881	Alto Neuroscience	ancestor	146273	ALTO-100	Phase 2 Clinical	['Major depressive disorder', 'Post traumatic stress disorder']	['Oral formulation', 'Small molecule therapeutic', 'Tablet formulation']	['Neurology/Psychiatric']	
1248993	MindRank AI	ancestor	151217	MDR-001	Preclinical	['Diabetes mellitus', 'Metabolic disorder', 'Obesity', 'Weight loss']	['Oral formulation', 'Small molecule therapeutic']	['Other/Miscellaneous', 'Endocrine/Metabolic']	
1010930	Prometheus Biosciences	ancestor	147661	PRA-052	Phase 1 Clinical	['Inflammatory bowel disease', 'Ulcerative colitis']	['Biological therapeutic', 'Intravenous formulation', 'Monoclonal antibody human', 'Subcutaneous formulation']	['Gastrointestinal']	
1010930	Prometheus Biosciences	ancestor	134284	PR-1800	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody', 'Parenteral formulation unspecified']	['Gastrointestinal']	Discovery
1010930	Prometheus Biosciences	ancestor	134106	PR-1100	Preclinical	['Inflammatory bowel disease']	['Biological therapeutic', 'Monoclonal antibody']	['Gastrointestinal']	
1010930	Prometheus Biosciences	ancestor	133824	PR-2100	Preclinical	['Inflammatory bowel disease']	['Biological therapeutic', 'Monoclonal antibody']	['Gastrointestinal']	
1010930	Prometheus Biosciences	ancestor	129305	TPR-15	No Development Reported	[]	['Biological therapeutic', 'Monoclonal antibody']	['Gastrointestinal']	Discovery
1010930	Prometheus Biosciences	ancestor	129304	PR-300	Discovery	['Inflammatory bowel disease']	['Small molecule therapeutic']	['Gastrointestinal']	
1010930	Prometheus Biosciences	ancestor	128388	PRA-023	Phase 2 Clinical	['Crohns disease', 'Inflammatory bowel disease', 'Scleroderma-associated interstitial lung disease', 'Ulcerative colitis']	['Biological therapeutic', 'Infusion', 'Intravenous formulation', 'Monoclonal antibody', 'Monoclonal antibody humanized', 'Subcutaneous formulation']	['Gastrointestinal', 'Respiratory']	
1010930	Prometheus Biosciences	ancestor	126324	PR-600	Preclinical	['Crohns disease', 'Inflammatory bowel disease', 'Ulcerative colitis']	['Biological therapeutic', 'Monoclonal antibody']	['Gastrointestinal']	
